BBlogFlow

Health-related barriers to employment costing Canada more than $100 billion: report - Benefits Canada.com

·2d ago
Source: Benefits Canada.com
Read the original article

This story deserves to be shared

Send it to someone who'd care, or post it on your networks.

Facebook Twitter Email

While health-related barriers to workforce participation cost Canada more than $100 billion in economic output in 2025, reducing those barriers by 25 per cent could recover more than $25 billion annually, according to a new report by Deloitte Canada.

“I don’t think the connection between health and the economy is necessarily new,” says Michelle Theroux, national health leader at Deloitte Canada. “But $25 billion is a lot of money. . . . We do believe health belongs on the competitiveness agenda and should be treated with the same discipline and measurement rigor that the country applies to trade, capital and other types of investments related to the economy.”

This article is an excerpt. To read the full content, visit the original source. Benefits Canada.com

Reactions

0 comments

No comments yet. Be the first to share your thoughts!

Facebook Twitter

Related articles

What Are the Recent Trends in Health Sector Employment - KFF

This updated chart collection uses federal labor data to compare jobs and wages in the health care sector with the rest of the economy. Health sector employment has grown steadily while job growth in other non-farm sectors has plateaued. Over the past year, the health sector added 378,500 jobs—a 2% increase—compared with 0.2% growth in non-health, non-farm employment. Health care wage growth has slowed slightly compared to other industries over the past three years. Health care jobs now account for 11.6% of all non-farm jobs, up from 10.7% a decade ago. Since 1990, health sector employment has grown over three times as much as all other non-health, non-farm employment sectors, increasing most in outpatient settings (up 40% since August 2016.)

KFF·

Bioengineer.org | Viral blips during HIV therapy are common and rarely signal treatment failure, Swedish study finds - European AIDS Treatment Group

Bioengineer.org news storyFor people living with HIV, modern antiretroviral therapy can suppress the virus to levels below what standard laboratory tests can detect. Yet some patients on long-term treatment experience a curious phenomenon: a single test result showing a small, transient amount of virus in the blood, followed by an immediate return to undetectable levels. These events, known as viral blips, have puzzled clinicians and researchers for years, raising questions about whether they represent harmless statistical noise, brief bursts of viral production from hidden reservoirs, or early warnings of impending treatment failure. A new nationwide Swedish study, published in BMC Infectious Diseases, offers one of the most comprehensive answers to date. Drawing on the Swedish national InfCareHIV cohort, researchers analyzed data from 4,210 treatment-naïve adults who began antiretroviral therapy from 1 January 2007 onward, with follow-up data extracted through 30 September 2020. The median observation time was 5.5 years, with some individuals followed for as long as 13.7 years.

European AIDS Treatment Group·

European Medical Journal | HIV linked to early signs of heart dysfunction - European AIDS Treatment Group

European Medical Journal news storyPeople living with HIV may experience subtle changes in heart muscle function even when conventional measures of cardiac performance remain normal, according to findings from a systematic review and meta-analysis. Researchers identified significantly impaired global longitudinal strain (GLS) among people with HIV compared with HIV-uninfected individuals, despite preserved left ventricular ejection fraction (LVEF) in both groups. The findings suggest that speckle-tracking echocardiography (STE) could provide additional information about early myocardial dysfunction in this population. Read the full news story here.

European AIDS Treatment Group·

Patient-centered financial navigation assistance helps reduce financial toxicity among cancer patients - Medical Xpress

Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.

Medical Xpress·